drugset / Trial / NCT00003362
Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma
RandomizedTreatment
Summary
RATIONALE: Vaccines made from peptides that are found on melanoma cells may make the body build an immune response and kill melanoma cells. Combining vaccine therapy with immune adjuvants, such as GM-CSF, Montanide ISA-51, or QS21, may be a more effective treatment for advanced melanoma. PURPOSE: Randomized phase II trial to study the effectiveness of gp 100-tyrosinase peptide vaccine with one of the immune adjuvants GM-CSF, Montanide ISA-51, or QS21 in treating patients who have stage III or stage IV melanoma.
Timeline
- Start
- 1998-05
- Primary completion
- 2001-02
- Completion
- 2001-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QS-21 | Other / unclassified | — | Subcutaneous |
| Subject | gp100 antigen | Peptide | — | Other |
| Subject | sargramostim | Protein / enzyme biologic | — | Other |
| Subject | tyrosinase peptide | Peptide | — | Other |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | — |